Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Homeopathic Drugs Bellis Perennis ו- Staphysagria on the Post-operative Recovery, of Women Undergoing Cesarean Section- (an Exploratory) Double Blind, Placebo Controlled Study
Brief Summary: The planned study will be conducted in a prospective, randomized, double blind placebo controlled manner. Two "anti-traumatic" Homeopathic remedies (Arnica montana and Staphysagria) will be used. The selection of these remedies was based on a previous trial that showed a statistical difference in Hemoglobin levels favoring pregnant women treated with these drugs following delivery.

The proposed study will focus on the post-operative recovery of women undergoing Cesarean section. According to Homeopathic principles, these two remedies are believed to improve the "vital force", and will therefore improve convalescence following surgery in the study group. The study will include 90 women between the ages of 18 and 50 years who are scheduled for elective Cesarean Section. Exclusion criteria are: obesity (above 100kg), malignancy, psychiatric illness, diabetes and multipara pregnancies. Participants will be inducted following a detailed explanation by an MD and signing of an informed consent form, and then subdivided randomly into three groups numbering 30 in each: Two groups will be treated with homeopathic drugs of varied doses, and the third will get a placebo remedy which is indistinguishable from the other drugs. Outcome measures will include: 1. Blood loss - as estimated by a reduction in serum Hemoglobin levels. 2. Pain -to be evaluated by a numerical rating score (NRS) 3. Analgesic use 4. Length of post-operative stay and complications. 5. Quality of life outcomes - to be assessed using the MOS SF-36 questionnaire at one and four weeks following surgery. Although not expected, adverse events will be monitored.

If, as we anticipate, the homeopathic treatment proves to be both safe and effective in shortening the duration of post-operative healing, this will have significant implications, with respect to both healthcare costs and patient suffering. It will also open the door for further research in the field of trauma medicine, as well as other stress-related illness.


Options:
A: Inclusion Criteria:

* 18 years or older
* full term singleton pregnancy
* undergoing elective cesarean delivery

Exclusion Criteria:

* Patients who have refused, are unable to give or have withdrawn consent
* Patients unable to communicate fluently in English
* Patients with American Society of Anesthesiologists (ASA) classification of 3 or greater
* Patients with chronic pain, or neuropathic analgesic drugs
* Patients in use of antidepressant and psychotropic drugs
* Patients with a history of opioid or intravenous drug abuse
* Patients with known allergy or contra-indication to any other drugs used in this trial
* Patients who have refused spinal anesthesia, or those in whom it is contra-indicated
* Patients with a history of previous cesarean delivery and persistent pain
B: Inclusion Criteria:

* women hospitalized for elective C. Section, from the 1st to 3rd pregnancies.
* Age \< 50 years
* Body weight \< 100 kg
* Signing of informed consent form

Exclusion Criteria:

1. suspected/proven malignancy
2. underlying Axis-1 psychiatric illness
3. age \< 18 years
4. diabetes mellitus (NIDDM/IDDM)
5. unable to comply with study proceedings
C: Inclusion Criteria:

1. Age range between 22 - 35 years
2. Patient willing to undergo C-section surgery
3. Patient having pains after one hour of post C-Section surgery
4. Patients who is conscious and oriented for device installation after anesthetic effect
5. Patient who completed required clinical and biochemical investigations as deemed necessary by the gynecologist after post C - section surgery.
6. No previous poor obstetrical outcome
7. No experience in Han's Acupoint nerve stimulator and TENS for other reasons.
8. Term pregnancy (\> 37 weeks of gestation).
9. Understands and is willing to participate in the clinical study and can comply with study procedures.
10. Normal cognitive and communicative ability as judged by clinical assessment and ability to complete self-reported questionnaires.

Exclusion Criteria:

1. Had been diagnosed with other diseases such as preoperative presence of maternal mental, neurological disease, affecting evaluation of pains and disease condition.
2. Had combined with gestational hypertension, gestational diabetes, gestational thyroid disease.
3. Had taken analgesic drugs
4. Had used diazepam, piperazine hydrochloride or other sedative, analgesic drugs in the stage of labor.
5. Were overweight or low pregnancy weight, Body mass index (\< 18.5 or \>25 kg/m2).
6. Patients who are not agreeing to receive painless labor and not sign the informed consent form.
7. Neonatal problem requiring immediate separation from the mother for medical care or NICU admittance.
8. Severe placental abruption.
9. Hydrops (accumulation of fluid or edema in fetus body tissue and cavities) if secondary to anemia or heart failure.
10. Known twin to twin transfusion syndrome (TTS).
11. Congenital anomalies that may hamper the procedure (gastroschisis, amphalacele, spina bifida).
12. Home birth.
13. Severe mental health problem
14. Hearing impairment.
15. Legal abortion
16. Twin pregnancy
17. Instrumental birth
18. Uterine anomalies with contraindication for vaginal birth. Eg: previous opening of uterine cavity, myomectomy, congenital abnormalities.
19. Placenta anomalies.
20. Placenta praevia, suspected acreta, increta, percreta especially after previous caesarean.
21. Fetal abnormalities, growth restriction.
22. Maternal complication with surgery.
23. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening; or subject or physician anticipates use of any of these therapies by the subject during the course of the study
24. Previous participation in the Treatment Phase of this Protocol
25. Malignant disease not in remission for five years or more that has been medically or surgically treated without evidence of metastases
26. Presence of one or more medical conditions, as determined by medical history, which seriously compromises the subject's ability to complete the study, including history of poor adherence with medical treatment, unstable pain intensity or pain medications 6 weeks prior to the study, renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this study: a) One or more abnormal blood biochemistry analyte result that is ≥ 3 times that of the upper limit of the normal range
27. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV)
28. American Heart Association (AHA) Class III and IV congestive heart failure (CHF), as defined by the following criteria: a) Class III: Symptoms with moderate exertion b) Class IV: Symptoms at rest or c) Cardiac pacemakers.
29. Subjects with a diagnosis of psychiatric disorders such as major depressive disorder, bipolar disorder, obsessive compulsive disorder, generalized anxiety, dysthymia or suicidality/suicide ideation
30. Subjects not willing to undergo treatment before discharge from the hospital.
D: Inclusion Criteria:

* greater than 36 weeks gestation
* primary C/S with Epidural for labor problems or breech presentation
* Repeat C/S with spinal

Exclusion Criteria:

* less than 36.0 week gestations
* vertical skin incisions
* classical or vertical hysterotomy incisions
* failed vaginal births after C/S (VBAC)
* past history of drug or alcohol abuse
* positive drug screens unless medical prescribed drugs
* general anesthesia
* Caesarean Hysterectomy
* primary C/S with spinal anesthesia

Answer: B